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Conclusions: Performed measurements were shown the similar as for 
rectum detector angular dependence of IN-VIVO bladder detector 
readings for Ir-192 radiation. Results make obvious that for more 
accurate probe calibration the angular testing of its sensitivity should 
be done. Angular and off-axial components of the diode response 
should be identified. The best angular ranges for performing the long-
term reproducibility calibrations should be recognized and appropriate 
marking on the catheter surface should be done. The fluoroscopic 
images, which are taken during treatment planning procedure, allow 
to find out the angle of the detector to direction of radiation coming 
from the radiation source and based on that appropriate correction 
factor can be estimated. As the final result of all these actions it can 
be achieved more agreement between planning treatment dose 
calculations and IN-VIVO measurements. 
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Purpose/Objective: Volumetric modulated arc radiotherapy (VMAT) or 
Rapid Arc (RA) is being widely used for highly conformal dose 
distribution and faster treatments as well. It is a system for intensity-
modulated radiotherapy treatment (IMRT) delivery that achieves high 
dose conformality by optimizing the dose rate, gantry speed, and the 
leaf positions of the dynamic multileaf collimator (DMLC). Stringent 
dosimetric verification is required for accurate delivery of planned 
dose from the treatment planning system (TPS). Recently, a novel 
ISORADTM (Sun Nuclear, USA)cylindrical diode was procured and the 
objective of this study was to perform the rapid arc patient-specific 
dosimetry with this diode. 
Materials and Methods: RapidArc patient-specific dosimetry was 
carried out for eight patients (n = 8) with carcinoma of prostate. All 
the patients were planned on Eclipse (8.6.1, Varian,USA) TPS with 6 
MV x-rays from a dual energy Novalis Tx linear accelerator (Varian, 
USA). A single arc was used for all the patients. Progressive Resolution 
Optimization (PRO) and Analytical Anisotropic Algorithm (AAA) were 
used for arc optimization and dose calculation respectively. 
Verification plan was generated in Eclipse for all the patients. For 
this, a solid water slab phantom (30 cm x 30 cm x 30 cm) with ISORAD 
diode was scanned in computed tomography (CT) machine (GE, USA). 
A separate indigenous adaptor was designed and fabricated for this 
diode to be used in these slabs. The dose was calculated at central 
axis and was noted. The same setup was simulated on linac and dose 
was measured at the isocentre. All measurements were compared 
with theTPS dose calculation via absolute point dose comparison. The 
film and ion chamber results were similarly compared with the ion 
chamber (FC65G, IBA, Sweden) measurements as well. Prior to this, 
the diode was calibrated against a reference ionization chamber at 
the same depth and the diode sensitivity correction was determined.  
Results: The diode readings were reproducible and the sensitivity 
correction factor was 1.10. Absolute point dose measurements agreed 
well with treatment planning system computed doses (ion chamber: 
mean deviation,1.2%, range, -0.5% to 2.9%; ISORAD: mean deviation, 
0.3%, SD 1.6, range, -0.4%to 2.8%). The institutional dosimetry 
acceptance criterion for IMRT/VMAT is ±3%. 
Conclusions: For pre-treatment plan verification of advanced 
treatment techniques volumetric modulated arc therapy, a fast and 
reliable dosimetric device is required. In this study, we investigated 
the suitability of ISORAD for verification of Rapidarc therapy plans. 
The measurements and dosimetry proves that ISORAD can be used for 
quantifying absolute dose as an alternative to ion chamber 
measurement. However, ion chamber measurements are 
recommended for absolute dose comparison. Moreover, this diode was 
found useful due to its cylindrical shape an ease of setup. 
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Purpose/Objective: To develop a protocol (irradiation procedure, 
action levels) for an external quality control of stereotactic beams of 
Cyberknife® with Equal-Estro laboratory. These preliminary studies 
involved seven French institutions. 
Materials and Methods: Equal-Estro provided a cubic water-
equivalent plastic phantom (so-called'mini-cube') containing four 
thermoluminescent detectors, TLDs, (TLD-100, Harshaw) and three 
radiochromic films (Gafchromic EBT2). This phantom was designed to 
be inserted in ananthropomorphic head phantom used to perform end-
to-end quality controls. The phantom had to be irradiated according 
to a protocol describing a target volume in which three TLDs were 
encompassed with a 5mm isotropic margin, and one organ at risk 
represented by the fourth TLD. A maximum dose of 4.1Gy was 
prescribed to the target volume. After irradiation in a single fraction, 
the 'mini-cube' phantom was returned to Equal-Estro laboratory to be 
analyzed and measured doses were compared to calculated doses. 
Absolute dose deviations were evaluated using the TLDs and gamma-
index analyses were performed on films. A preliminary study was 
performed to determine the statistical accuracy and the most 
appropriate action levels to be applied to all tests.  
Results: Intrinsic TLD dose measurement on Cyberknife beams is 
reliable as reproducibility was of about 1.7% (1 SD) for a single beam. 
Dose deviations were lower than 5% for PTV-TLDs in most of the tested 
centers but larger deviations were observed on the OAR-TLD in some 
institutions. Investigations performed subsequently have identified the 
non homogeneous dose distribution onthe TLD to be the main cause of 
measured deviations. Analyses of different gamma-index criteria 
allowed choosing the 5%/2mm as the most appropriate tolerance level 
for gamma index tests, which is consistent with the film analysis 
procedure uncertainty (mostly due to the matching uncertainty of 
dose distributions). 
Conclusions: An accuracy of 5% can be achieved if dose 
inhomogeneity in TLDs volumes is reduced in the planning process. 
The final version of the planning protocol will include the use of a PTV 
and a PRV around the TLDs, with constraints on dose homogeneity on 
the DVHs. This work will be followed by a second round of irradiations 
using the improved version of the procedure. 
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Purpose/Objective: The aim of this work is to characterize the Dosi-
Secure® detector for in vivo dosimetry in High Energy photon beams. 
Measurements are first performed on phantom and then on patients to 
determine the level of accuracy of the device in clinical use. 
Materials and Methods: TheDosi-Secure® system consists of a wireless 
and passive detector (Dosi-Patch®), a tactile reader (Dosi-Pad®) and 
an associated software. This system ensures the traceability of in vivo 
dosimetry for each patient during the radiotherapy session. The 
detector is based on a specific PMOS technology. A build-up cap is 
incorporated to allow measurements at the maximum depth dose 
(entrance dose). The dosimeters are calibrated by the manufacturer; 
there have no embedded correction factors. The dosimeters are 
placed on the surface of a water equivalent slab phantom and 
irradiated with 8MV and 25MV photon beams. The influence of the 
variation of different parameters on detector response is evaluated: 
field size (open and wedged beams), SSD and angular incidence. All 
